Journey Medical (DERM)
(Delayed Data from NSDQ)
$7.27 USD
+0.22 (3.12%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $7.26 -0.01 (-0.14%) 5:20 PM ET
5-Strong Sell of 5 5
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DERM 7.27 +0.22(3.12%)
Will DERM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DERM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DERM
New Strong Sell Stocks for September 4th
Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates
DERM: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
Other News for DERM
20 Day Moving Average Resistance appears for DERM after 1.67% move
20 Day Moving Average Resistance appears for DERM after 0.7% move
Is DERM primed for downward momentum? 20 Day Moving Average Resistance shows up after climbing 0.14%
DERM Fell Below 20 Day Moving Average on September 12
DERM Crossed Above 50 Day Moving Average on September 11